Moderna is trading 8.58% down now at $185.24, with the sell-the-news reaction continuing after positive Phase 3 melanoma-vaccine results. - The vaccine combination reduced recurrence-or-death risk by 42%; shares had nearly quadrupled through Wednesday’s close. - Analysts raised questions about how broadly the approach could work in other cancers. - Reuters reported shares closed more than 17% lower on October 22 after the results leaked.